Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren plus losartan versus losartan for regression of left ventricular hypertrophy in overweight adults with essential hypertension
2005-000856-34Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in essential hypertension and left ventricular hypertrophy (LVH) comparing Aliskiren + losartan, Losartan and Aliskiren (3 arms). Primary endpoint: Key objective 1. Started Jun 2005; status: completed.
02
Drugs
aliskirenlosartan
03
Conditions
essential hypertensionleft ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on 2005-000856-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000856-34.